SOUTH SAN FRANCISCO, CA, USA I January 9, 2015 I CoMentis, Inc and Anvyl, LLC announced today that APN1125, the first compound from their Alpharmagen joint venture, has begun dosing subjects in a Phase 1 clinical trial. APN1125 is a partial agonist of the alpha 7 nicotinic acetylcholine receptor and has shown activity in animal models of cognitive disorders.
Dr. Terence Kelly, CEO of CoMentis stated, “We are extremely excited to announce the initiation of human trials for APN1125. There are numerous studies that indicate that alpha 7 modulators have the potential to become significant therapeutic agents. We are pleased that the Alpharmagen JV with Anvyl has reached this milestone in only our second year, and we look forward to additional therapeutic agents advancing into development soon.”
Dr. David Putman, Chief Operating Officer at Anvyl, LLC commented: “Modulation of the alpha 7 channel shows tremendous promise for the amelioration of cognitive deficits in particularly underserved patient groups. The Alpharmagen JV has continued the pioneering work of CoMentis and Anvyl in this therapeutic area, has rapidly produced its first clinical candidate, and will continue to pursue this target with additional clinical agents.”
About Alpharmagen:
Alpharmagen, Inc., headquartered in South San Francisco, California, is a joint venture between CoMentis, Inc. and Anvyl, LLC,. The company is engaged in the discovery and development of alpha 7 nicotinic acetylcholine receptor activators, including partial agonists and positive allosteric modulators, to treat cognitive disorders associated with Schizophrenia and other conditions.
About CoMentis:
CoMentis, Inc., a biotech company, engages in the research, discovery, and development of small-molecule drugs to treat neurological diseases, with a focus on Alzheimer’s disease and Schizophrenia. The company advanced the first beta-secretase inhibitor into the clinic for the treatment of Alzheimer’s disease in 2006. The current focus of the company is the development of nicotinic acetylcholine receptor modulators for the treatment of cognitive disorders. CoMentis, Inc. was founded in 2004 and is based in San Francisco, California. For more information on CoMentis, please visit the company website at www.comentis.com.
About Anvyl:
Anvyl, LLC is based in Irvine, CA and specializes in the discovery and development of drugs for serious neurologic and psychiatric disorders by utilizing allosteric modulation of ion channels to correct disease. AVL-3288, the company’s first in class type I positive allosteric modulator of the alpha7 nicotinic acetylcholine receptor, is in clinical trials for the treatment of cognitive impairment associated with schizophrenia. For more information about Anvyl, please visit the Company’s website at: www.anvylllc.com.
SOURCE: CoMentis
Post Views: 166
SOUTH SAN FRANCISCO, CA, USA I January 9, 2015 I CoMentis, Inc and Anvyl, LLC announced today that APN1125, the first compound from their Alpharmagen joint venture, has begun dosing subjects in a Phase 1 clinical trial. APN1125 is a partial agonist of the alpha 7 nicotinic acetylcholine receptor and has shown activity in animal models of cognitive disorders.
Dr. Terence Kelly, CEO of CoMentis stated, “We are extremely excited to announce the initiation of human trials for APN1125. There are numerous studies that indicate that alpha 7 modulators have the potential to become significant therapeutic agents. We are pleased that the Alpharmagen JV with Anvyl has reached this milestone in only our second year, and we look forward to additional therapeutic agents advancing into development soon.”
Dr. David Putman, Chief Operating Officer at Anvyl, LLC commented: “Modulation of the alpha 7 channel shows tremendous promise for the amelioration of cognitive deficits in particularly underserved patient groups. The Alpharmagen JV has continued the pioneering work of CoMentis and Anvyl in this therapeutic area, has rapidly produced its first clinical candidate, and will continue to pursue this target with additional clinical agents.”
About Alpharmagen:
Alpharmagen, Inc., headquartered in South San Francisco, California, is a joint venture between CoMentis, Inc. and Anvyl, LLC,. The company is engaged in the discovery and development of alpha 7 nicotinic acetylcholine receptor activators, including partial agonists and positive allosteric modulators, to treat cognitive disorders associated with Schizophrenia and other conditions.
About CoMentis:
CoMentis, Inc., a biotech company, engages in the research, discovery, and development of small-molecule drugs to treat neurological diseases, with a focus on Alzheimer’s disease and Schizophrenia. The company advanced the first beta-secretase inhibitor into the clinic for the treatment of Alzheimer’s disease in 2006. The current focus of the company is the development of nicotinic acetylcholine receptor modulators for the treatment of cognitive disorders. CoMentis, Inc. was founded in 2004 and is based in San Francisco, California. For more information on CoMentis, please visit the company website at www.comentis.com.
About Anvyl:
Anvyl, LLC is based in Irvine, CA and specializes in the discovery and development of drugs for serious neurologic and psychiatric disorders by utilizing allosteric modulation of ion channels to correct disease. AVL-3288, the company’s first in class type I positive allosteric modulator of the alpha7 nicotinic acetylcholine receptor, is in clinical trials for the treatment of cognitive impairment associated with schizophrenia. For more information about Anvyl, please visit the Company’s website at: www.anvylllc.com.
SOURCE: CoMentis
Post Views: 166
